APLS
Apellis Pharmaceuticals Inc
3.40$
-0.1%
vs. previous close
Closing price · As of: Aug 13, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 8.8% | 20.3% | 13.6% | 12.0% | 11.8% | 17.0% | 19.2% | 20.6% | 7.9% | 5.3% | 14.9% | 15.2% | 9.9% | |
| 91.2% | 79.7% | 86.4% | 88.0% | 88.2% | 83.0% | 80.8% | 79.4% | 92.1% | 94.7% | 85.1% | 84.8% | 90.1% | |
| 100.7% | 71.9% | 47.3% | 49.2% | 39.0% | 45.0% | 35.9% | 51.8% | 37.5% | 14.9% | 37.1% | 28.7% | 25.9% | |
| 117.3% | 131.9% | 96.8% | 75.2% | 64.1% | 62.0% | 18.0% | 77.5% | 73.5% | 31.1% | 73.6% | 46.3% | 49.3% | |
| 218.0% | 203.9% | 144.1% | 124.0% | 103.0% | 107.0% | 93.1% | 129.4% | 110.8% | 46.0% | 110.7% | 75.0% | 75.2% | |
| -126.8% | -124.2% | -57.7% | -36.0% | -14.7% | -24.0% | -12.3% | -50.0% | -18.6% | 48.7% | -25.6% | 9.9% | 14.9% | |
| 7.7% | 6.6% | 5.1% | 4.0% | 4.7% | 6.4% | 5.4% | 6.6% | 6.2% | 2.5% | 5.4% | 3.8% | 3.9% | |
| -128.3% | -126.8% | -59.5% | -38.4% | -18.8% | -28.9% | -17.0% | -55.1% | -23.4% | 47.2% | -29.3% | 7.1% | 12.2% | |
| 0.2% | 0.2% | 1.0% | 0.1% | 0.1% | 0.3% | 0.1% | 0.2% | 0.3% | 0.1% | 0.2% | 0.2% | 0.2% | |
| -128.5% | -127.0% | -60.5% | -38.5% | -18.9% | -29.2% | -17.1% | -55.3% | -23.6% | 47.0% | -29.5% | 7.0% | 12.1% | |
| -120.1% | -119.8% | -54.1% | -34.1% | -13.9% | -22.3% | -11.3% | -48.2% | -16.9% | 49.7% | -23.7% | 11.1% | 16.3% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: August 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.